The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer
Abstract
Aiming at improved therapeutic efficacies, the combination of chemotherapy and radiotherapy (chemo-radiotherapy) has been widely studied and applied in clinic. However, the hostile characteristics of tumor microenvironment such as hypoxia often limit the efficacies in both types of cancer therapies. Herein, catalase (CAT), an antioxidant enzyme, is encapsulated inside liposomes constituted by cisplatin (IV)-prodrug-conjugated phospholipid, forming CAT@Pt (IV)-liposome for enhanced chemo-radiotherapy of cancer. After being loaded inside liposomes, CAT within CAT@Pt (IV)-liposome shows retained and well-protected enzyme activity, and is able to trigger decomposition of H 2 O 2 produced by tumor cells, so as to produce additional oxygen for hypoxia relief. As the result, treatment of CAT@Pt (IV)-liposome induces the highest level of DNA damage in cancer cells after X-ray radiation compared to the control groups. In vivo tumor treatment further demonstrates a remarkably improved therapeutic outcome in chemo-radiotherapy with such CAT@Pt (IV)-liposome nanoparticles. Hence, an exquisite type of liposome-based nanoparticles is developed in this work by integrating cisplatin-based chemotherapy and catalase-induced tumor hypoxia relief together for combined chemo-radiotherapy with great synergistic efficacy, promising for clinical translation in cancer treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, in situ generation of oxygen using catalase as an enzyme is attractive because it is self-responsive to hydrogen peroxide (H2O2) and does not require pre-treatment with oxygen ( 3 O2).18,19,24”
From Catalase-Integrated Hyaluronic Acid as Nanocarriers for Enhanced Photodynamic Therapy in Solid Tumor (2019) · cites this paper as [19]
Citations
Cites
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010187 · Cited by 3,470
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M. H., Pajak, T. F., Weber, R. S., Morrison, W. H., Glisson, B. S., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,161
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
The Department of Veterans Affairs Laryngeal Cancer Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242402 · Cited by 2,755
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J., Hickey, H., Beger, H. G., Fernández‐Cruz, L., Dervenis, C., LACAINE, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,709
D'Amico, A., Whittington, R., Malkowicz, S., Schultz, D., Blank, K., Broderick, G., Tomaszewski, J., Renshaw, A., Kaplan, I., Beard, C., et al. (1998) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.280.11.969 · Cited by 2,697
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke‐Pearson, D. L., & Insalaco, S. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401502 · Cited by 2,662
A simple method for determination of serum catalase activity and revision of reference range
Góth, L. (1991) · Clinica Chimica Acta · doi:10.1016/0009-8981(91)90067-m · Cited by 2,391
Al‐Sarraf, M., LeBlanc, M. L., Giri, P. G., Fu, K. K., Cooper, J. S., Vuong, T., Forastiere, A. A., Adams, G. L., Sakr, W., Schuller, D. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1310 · Cited by 2,218
Cited by
Sorted by citations
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Tian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., Nice, E. C., Xie, N., Huang, C., & Shen, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01320-5 · Cited by 458
Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization
Xie, J., Gong, L., Zhu, S., Yong, Y., Gu, Z., & Zhao, Y. (2018) · Advanced Materials · doi:10.1002/adma.201802244 · Cited by 418
Precise nanomedicine for intelligent therapy of cancer
Chen, H., Gu, Z., An, H., Chen, C., Chen, J., Cui, R., Chen, S., Chen, W., Chen, X., Chen, X. S., et al. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9397-5 · Cited by 413
Self-citationX-ray-activated nanosystems for theranostic applications
Chen, X., Song, J., Chen, X. S., & Yang, H. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00921j · Cited by 403
Metadata
- Authors
- Zhang, R., Song, X., Liang, C., Yi, X., Song, G., Chao, Y., Yang, Y., Yang, K., Feng, L., & Liu, Z.
- Affiliations
- Soochow University (CN)
- Corresponding author
- Feng, Liangzhu
- Liu, Zhuang
- ORCID
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 138
- Pages
- 13-21
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2616024862
- Cited by
- 255
- References
- 45
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 21 · 2023: 31 · 2022: 41 · 2021: 34 · 2020: 39 · 2019: 34 · 2018: 25 · 2017: 6
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biomaterials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology (MOST) of China (2016YFA0201200)
- National Natural Science Fundation of China (51525203)
- Collaborative Innovation Center of Suzhou Nano Science and Technology
- Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- catalase, cisplatin prodrug, liposomes, tumor hypoxia, chemoradiotherapy, radiotherapy, hydrogen peroxide decomposition, DNA damage, tumor microenvironment, cancer therapy
- MeSH terms
- Tumor Hypoxia, Animals, Antineoplastic Agents, Antioxidants, Catalase, Cisplatin, DNA Damage, Female, Hydrogen Peroxide, Liposomes, Mice, Inbred BALB C, Neoplasms, Neoplasms, Experimental, Phospholipids, Prodrugs, Cell Line, Tumor, Mice, Nanoparticles, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
